Autopsy report · NCT00473551

Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies

“Terminated due to slow accrual.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 6 months before it stopped.
• 4 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

M.D. Anderson Cancer Center

Sponsor type

University, hospital or other

Conditions

Leukemia; Lymphoma; Myeloma

Interventions

Rituximab; Cyclophosphamide; Fludarabine; Mesna; Radiation Treatment; Stem Cell Transplantation (SCT)

Participants

4

Sites

1

Countries

United States

Trials that died the same way

• Evaluating the Effects of an Exercise Intervention on the Gut Microbiota in Stage II-III Colorectal Cancer Survivors
  “Terminated due to low accrual.” (92% match in meaning)
• Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer
  “Terminated prematurely due to low accrual.” (88% match in meaning)
• Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)
  “Terminated due to poor accrual” (85% match in meaning)
• Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer
  “Terminated due to inadequate rate of accrual.” (83% match in meaning)
• Efficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to Severe Keratosis Pilaris, a Prospective Study
  “terminated due to administrative reasons.” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.